Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus PALSONIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus PALSONIFY.
CYCLOCORT vs PALSONIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Selective serotonin reuptake inhibitor (SSRI) that enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing extracellular serotonin levels in the brain.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
70 mg/m2 IV every 3 weeks. Infusion over 60 minutes.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal half-life 12 hours (range 10–14 h) in healthy adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid